Wells Fargo’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-15,407
| Closed | -$24.5K | – | 7734 |
|
|
2024
Q1 | $24.5K | Buy |
15,407
+1,476
| +11% | +$2.19K | ﹤0.01% | 5520 |
|
|
2023
Q4 | $12K | Buy |
13,931
+2,651
| +24% | +$2.33K | ﹤0.01% | 5787 |
|
|
2023
Q3 | $12.1K | Sell |
11,280
-5,784
| -34% | -$12K | ﹤0.01% | 5754 |
|
|
2023
Q2 | $44.2K | Buy |
17,064
+9,021
| +112% | +$32.2K | ﹤0.01% | 5470 |
|
|
2023
Q1 | $32.8K | Buy |
8,043
+7,043
| +704% | +$32.6K | ﹤0.01% | 5393 |
|
|
2022
Q4 | $5.02K | Sell |
1,000
-459
| -31% | -$2.88K | ﹤0.01% | 5770 |
|
|
2022
Q3 | $19K | Sell |
1,459
-394
| -21% | -$5.97K | ﹤0.01% | 5440 |
|
|
2022
Q2 | $24K | Sell |
1,853
-10,819
| -85% | -$150K | ﹤0.01% | 5368 |
|
|
2022
Q1 | $193K | Sell |
12,672
-6,143
| -33% | -$95.8K | ﹤0.01% | 5001 |
|
|
2021
Q4 | $334K | Buy |
18,815
+523
| +3% | +$10K | ﹤0.01% | 4976 |
|
|
2021
Q3 | $384K | Sell |
18,292
-25,040
| -58% | -$551K | ﹤0.01% | 4813 |
|
|
2021
Q2 | $854K | Buy |
43,332
+27,531
| +174% | +$644K | ﹤0.01% | 4309 |
|
|
2021
Q1 | $460K | Sell |
15,801
-20,177
| -56% | -$565K | ﹤0.01% | 4727 |
|
|
2020
Q4 | $1.09M | Sell |
35,978
-15,135
| -30% | -$331K | ﹤0.01% | 3970 |
|
|
2020
Q3 | $813K | Sell |
51,113
-32,679
| -39% | -$596K | ﹤0.01% | 4013 |
|
|
2020
Q2 | $1.65M | Buy |
83,792
+46,661
| +126% | +$892K | ﹤0.01% | 3406 |
|
|
2020
Q1 | $458K | Buy |
37,131
+11,794
| +47% | +$193K | ﹤0.01% | 4104 |
|
|
2019
Q4 | $469K | Buy |
25,337
+21,917
| +641% | +$320K | ﹤0.01% | 4426 |
|
|
2019
Q3 | $47K | Buy |
3,420
+3,370
| +6,740% | +$50.6K | ﹤0.01% | 5578 |
|
|
2019
Q2 | $1K | Buy |
+50
| New | +$732 | ﹤0.01% | 6304 |
|
Wells Fargo's NGM Position: Q2 2024 in Review
Wells Fargo sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 15,407 shares — an estimated $24.5K sold.
Wells Fargo first reported a position in NGM in Q2 2019 and held it in 20 quarters. The position peaked at $1.65M in Q2 2020. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.
- Wells Fargo reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Wells Fargo sold 15,407 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $24.5K.
- Wells Fargo first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 20 quarters.
- Wells Fargo's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $1.65M in Q2 2020.
- 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.